Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.54 |
| ▸ | MAP3K5 | Q99683 | 10/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | CBLB | Q13191 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19965120 | 0.87 | SMN1; SMN2 (0.46) | CYP11B2MAP3K5NPC1RAB9AFFAR4 | |
| SCHEMBL19965003 | 0.87 | CYP11B2 (0.38) | CYP11B2MAP3K5FFAR4CYP11B1MKNK1 | |
| SCHEMBL19965178 | 0.86 | PRKCA (0.46) | CYP11B2MAP3K5NPC1RAB9APKM | |
| SCHEMBL19965013 | 0.86 | CYP11B2 (0.43) | CYP11B2MAP3K5NPC1RAB9APKM | |
| SCHEMBL19965052 | 0.84 | CYP11B2 (0.56) | CYP11B2MAP3K5NPC1RAB9APKM | |
| SCHEMBL19965112 | 0.84 | FFAR4 (0.36) | CYP11B2MAP3K5FFAR4MKNK1CBLB | |
| SCHEMBL19965030 | 0.80 | CYP11B2 (0.54) | CYP11B2MAP3K5NPC1RAB9APKM | |
| SCHEMBL19965105 | 0.80 | HRH4 (0.42) | CYP11B2FFAR4CYP11B1MKNK1 | |
| SCHEMBL21124472 | 0.75 | FFAR4 (0.60) | CYP11B2FFAR4CYP11B1MKNK1 | |
| SCHEMBL1721366 | 0.73 | FFAR4 (0.68) | CYP11B2NPC1RAB9APKMFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183231-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | Valo Health, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183231-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | Valo Health, LLC | 2023-06-15 | — | — | US | disclosed |
| US-11548886-B2 | Monocyclic compounds useful as GPR120 modulators | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210101896-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | Valo Health, LLC | 2021-04-08 | — | — | US | disclosed |
| US-10800773-B2 | Monocyclic compounds useful as GPR120 modulators | INTEGRAL HEALTH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190202821-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | Valo Health, LLC | 2019-07-04 | — | — | US | disclosed |
| WO-2018049324-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | NUMERATE, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548886-B2 | Monocyclic compounds useful as GPR120 modulators | GPR119, GPR180, GPR65 | CYP11B2 571/4885MAP3K5 2081/4885NPC1 360/4885 |
| US-10800773-B2 | Monocyclic compounds useful as GPR120 modulators | GPR119, GPR180, GPR65 | CYP11B2 571/4885MAP3K5 2081/4885NPC1 360/4885 |
| US-20210101896-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | CYP11B2 571/4885MAP3K5 2081/4885NPC1 360/4885 |
| US-20190202821-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | CYP11B2 571/4885MAP3K5 2081/4885NPC1 360/4885 |
| US-20230183231-A1 | MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | CYP11B2 571/4885MAP3K5 2081/4885NPC1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.